Liquid Biopsy

Please click here to register

December 6, 2022 – Virtual Event

10:00-10:35am  EST

Practical Applications of Liquid Biopsy Across Multiple Tumor Types

Erica L. Carpenter, MBA, PhD, Director, Liquid Biopsy Laboratory; Research Assistant Professor, Department of Medicine, Division of Hematology/Oncology, University of Pennsylvania

During this presentation Dr. Carpenter will frame latest, mostly clinical applications, of liquid biopsy for multiple different solid tumor types within the context of the patient journey. She will look at liquid biopsy use for diagnosis, therapy selection, and disease surveillance and detection of minimal residual disease (MRD).

10:40-11:15am EST

Early Detection of Cancer Using Cell-free DNA Fragmentomes

Victor Velculescu, MD, PhD, Professor of Oncology, Johns Hopkins University School of Medicine; Co-Director, Cancer Genetics and Epigenetics, Sidney Kimmel Cancer Center; Founder, Delfi Diagnostics

The presentation will be focused on a new generation of liquid biopsy approaches that provide high performing and cost effective analyses, allowing for tests for early detection and other cancer-related applications to be widely available in the US and around the world.

11:20am-12:00pm  EST 

Navigating the Toughest Challenges of Immunotherapy with the EpiSwitch® CiRT

Steven Mamus, MD, Medical Director,  Cancer Center of Sarasota-Manatee, Sarasota and Bradenton, Florida

12:05-12:35pm  EST 

Integrating Both Solid Tissue and Liquid Biopsy Strategies in Clinical Practice and Development

Nike Beaubier, MD, Senior Vice President, Life Science Pathology, Tempus Lab

This presentation will begin with an introduction in Tempus’ offerings including the 523 gene xF+ panel, and then explore the benefits of using concurrent solid tissue and liquid biopsy testing and longitudinal liquid biopsy testing in the clinic and how to integrate these strategies into clinical development.

12:40-1:10pm  EST 

Advances in Liquid Biopsy for Drug Development

David Fabrizio, MD, Vice President, Early Clinical Development, Foundation Medicine